Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,743 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Subgroup variations in bone mineral density response to zoledronic acid after hip fracture.
Magaziner JS, Orwig DL, Lyles KW, Nordsletten L, Boonen S, Adachi JD, Recknor C, Colón-Emeric CS, Mesenbrink P, Bucci-Rechtweg C, Su G, Johnson R, Pieper CF. Magaziner JS, et al. Among authors: su g. J Bone Miner Res. 2014 Dec;29(12):2545-51. doi: 10.1002/jbmr.2283. J Bone Miner Res. 2014. PMID: 24839241 Free PMC article. Clinical Trial.
Zoledronic acid results in better health-related quality of life following hip fracture: the HORIZON-Recurrent Fracture Trial.
Adachi JD, Lyles KW, Colón-Emeric CS, Boonen S, Pieper CF, Mautalen C, Hyldstrup L, Recknor C, Nordsletten L, Moore KA, Bucci-Rechtweg C, Su G, Eriksen EF, Magaziner JS. Adachi JD, et al. Among authors: su g. Osteoporos Int. 2011 Sep;22(9):2539-49. doi: 10.1007/s00198-010-1514-9. Epub 2011 Jan 20. Osteoporos Int. 2011. PMID: 21249332 Clinical Trial.
Once-yearly zoledronic acid in older men compared with women with recent hip fracture.
Boonen S, Orwoll E, Magaziner J, Colón-Emeric CS, Adachi JD, Bucci-Rechtweg C, Haentjens P, Kaufman JM, Rizzoli R, Vanderschueren D, Claessens F, Sermon A, Witvrouw R, Milisen K, Su G, Lyles KW; HORIZON Recurrent Fracture Trial. Boonen S, et al. Among authors: su g. J Am Geriatr Soc. 2011 Nov;59(11):2084-90. doi: 10.1111/j.1532-5415.2011.03666.x. Epub 2011 Oct 21. J Am Geriatr Soc. 2011. PMID: 22091563 Clinical Trial.
The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT).
Black DM, Reid IR, Boonen S, Bucci-Rechtweg C, Cauley JA, Cosman F, Cummings SR, Hue TF, Lippuner K, Lakatos P, Leung PC, Man Z, Martinez RL, Tan M, Ruzycky ME, Su G, Eastell R. Black DM, et al. Among authors: su g. J Bone Miner Res. 2012 Feb;27(2):243-54. doi: 10.1002/jbmr.1494. J Bone Miner Res. 2012. PMID: 22161728 Free PMC article. Clinical Trial.
Reduction in the risk of clinical fractures after a single dose of zoledronic Acid 5 milligrams.
Reid IR, Black DM, Eastell R, Bucci-Rechtweg C, Su G, Hue TF, Mesenbrink P, Lyles KW, Boonen S; HORIZON Pivotal Fracture Trial and HORIZON Recurrent Fracture Trial Steering Committees. Reid IR, et al. Among authors: su g. J Clin Endocrinol Metab. 2013 Feb;98(2):557-63. doi: 10.1210/jc.2012-2868. Epub 2013 Jan 4. J Clin Endocrinol Metab. 2013. PMID: 23293335 Clinical Trial.
The incidence of osteonecrosis of the jaw in patients receiving 5 milligrams of zoledronic acid: data from the health outcomes and reduced incidence with zoledronic acid once yearly clinical trials program.
Grbic JT, Black DM, Lyles KW, Reid DM, Orwoll E, McClung M, Bucci-Rechtweg C, Su G. Grbic JT, et al. Among authors: su g. J Am Dent Assoc. 2010 Nov;141(11):1365-70. doi: 10.14219/jada.archive.2010.0082. J Am Dent Assoc. 2010. PMID: 21037195 Clinical Trial.
Clinical risk factors for recurrent fracture after hip fracture: a prospective study.
Colón-Emeric CS, Lyles KW, Su G, Pieper CF, Magaziner JS, Adachi JD, Bucci-Rechtweg CM, Haentjens P, Boonen S; HORIZON Recurrent Fracture Trial. Colón-Emeric CS, et al. Among authors: su g. Calcif Tissue Int. 2011 May;88(5):425-31. doi: 10.1007/s00223-011-9474-4. Epub 2011 Feb 18. Calcif Tissue Int. 2011. PMID: 21331567 Clinical Trial.
2,743 results